Advantages of the Vegf Inhibitor, Macugen: A More Favourable Toxicity Profile

Koen Poesen; Thierry Janssens; Diether Lambrechts; Peter Carmeliet; Edward M. Conway

Related publications

Article2020

Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib

Panagiotis Efentakis, Hendrik Doerschmann, Claudius Witzler, Svenja Siemer, Panagiota Nikolaou, Efstathios Kastritis, Roland H. Stauber, Meletios A Dimopoulos, Philip Wenzel, Ioanna Andreadou, Evangelos Terpos

Article2004

Anti-HIV activity profile of a novel CCR5 inhibitor, AMD887, in combination with the CXCR4 inhibitor AMD070

Dominique Schols, Kurt Vermeire, Sigrid Hatse, Katrien Princen, De Clercq Erik, Gary Calandra, Simon P. Fricker, Kim L. Nelson, J Labrecque, David Bogucki, Ya-Shi Zhou, Renato T. Skerlj, Gary Bridger

Article2007

The Cyclophilin Inhibitor Debio-025 is a Potent Inhibitor of Hepatitis C Virus Replication in vitro With a Unique Resistance Profile

Lotte Coelmont, Jan Paeshuyse, Suzanne J. F. Kaptein, Inge Vliegen, Ajay Kaul, De Clercq Erik, Brigitte Rosenwirth, Piétro Scalfaro, R. Crabbé, Ralf Bartenschlager

Report2023

A meta-analysis of VEGF inhibitor efficacy in patients with liver metastases across cancer types.

Jordan W. Conway, Jorja Braden, Serigne Lo, Richard A Scolyer, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long, Inês Pires da Silva

Article2022

Unveiling toxicity profile for food risk components: A manually curated toxicological databank of food-relevant chemicals

Xing-Xing Shi, Fan Wang, Zhi-Zheng Wang, Guang-Yi Huang, Min Li, Jesus Simal Gandara, Ge‐Fei Hao, Guang‐Fu Yang